Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

A Pair of Gene Splice Isoforms Has Opposite Effects on Cancer Development

By BiotechDaily International staff writers
Posted on 21 Apr 2014
ADVERTISEMENT
SARTORIUS AG
Two distinct splice isoforms of the MAP kinase interacting serine/threonine kinase 2 (MKNK2) gene have dramatically different roles in cancer development and growth.

It is known that the protein products of MKNK2 phosphorylate the eukaryotic initiation factor 4E (eIF4E), thus playing important roles in the initiation of mRNA translation, oncogenic transformation, and malignant cell proliferation. However, it has come to light that MKNK2 is alternatively spliced with the two splicing isoforms having different last exons: Mnk2a, which contains a MAPK-binding domain, and Mnk2b, which lacks it.

Investigators at the Hebrew University of Jerusalem (Israel) reported in the April 10, 2014, online edition of the journal Cell Reports that the Mnk2a isoform was a tumor suppressor that was downregulated in human cancers. This isoform interacted with, phosphorylated, and activated p38-MAPK, leading to activation of its target genes and to p38alpha-mediated cell death. Thus, Mnk2a downregulation by alternative splicing was a tumor suppressor mechanism that was lost in some breast, lung, and colon tumors.

On the other hand, the Mnk2b isoform was found to be pro-oncogenic and did not activate p38-MAPK, while still enhancing eIF4E phosphorylation.

These results suggested that Mnk2 alternative splicing served as a switch in several cancers to downregulate a tumor suppressor isoform (Mnk2a) that activates the p38-MAPK stress pathway and to induce an isoform (Mnk2b) that does not activate this pathway and is pro-oncogenic.

"The mechanism we discovered explains how cancer cells eliminate the anticancer form of Mnk2 without changing their DNA, and how they become resistant to anticancer treatments—a problem which exists for almost every cancer treatment today," said senior author Dr. Rotem Karni, senior lecturer of biochemistry and molecular biology at the Hebrew University of Jerusalem.

Related Links:

Hebrew University of Jerusalem 




Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.